TCS Industries Limited (China-sourced API supplier) supplies Cidofovir — API CAS 113852-37-2 for pharmaceutical B2B procurement — COA, MSDS, and technical documentation available on request.
> Overview
| Product Name | Cidofovir |
|---|---|
| Structural Formula |  |
| CAS Number | 113852-37-2 |
| Molecular Formula | C8H14N3O6P |
| Molecular Weight | 279.19 g/mol |
| InChIKey | VWFCHDSQECPREK-LURJTMIESA-N |
| SMILES | Available on request where applicable |
| Appearance | White to off-white crystalline powder |
| Purity / Grade | By agreed specification and batch COA |
| Storage | Store at controlled room temperature |
Cidofovir (CAS 113852-37-2) is an acyclic nucleotide phosphonate antiviral with the formula C₈H₁₄N₃O₆P (MW 279.19). It is an analog of cytidine monophosphate that inhibits viral DNA polymerase. Cidofovir is used for CMV retinitis in AIDS patients and has broad-spectrum activity against DNA viruses (herpes, adeno, pox, polyoma). It is on the WHO Model List of Essential Medicines.
TCS Industries Limited, a Hong Kong-based trading and sourcing company, supplies Cidofovir API in pharmaceutical grade for global procurement programs.
> Applications
Antiviral therapy for CMV and DNA viruses
Cidofovir is phosphorylated intracellularly by cellular kinases (not viral thymidine kinase), producing the active diphosphate form that competitively inhibits viral DNA polymerase. This mechanism provides activity against acyclovir-resistant and ganciclovir-resistant strains. IV cidofovir 5 mg/kg every 2 weeks is used for CMV retinitis. De Clercq et al. (Clin Microbiol Rev, 2003, 16:569–596) reviewed the broad-spectrum activity of cidofovir and related acyclic nucleotide phosphonates against DNA viruses and their clinical applications.
Off-label and investigational uses
Cidofovir is used off-label for BK polyomavirus nephropathy in transplant recipients, adenovirus infections in immunocompromised patients, and recurrent respiratory papillomatosis (intralesional injection). Topical cidofovir (1–3% cream) is investigated for HPV-related lesions and molluscum contagiosum.
> Sourcing & Supply
TCS Industries Limited supports development, qualification and commercial purchasing discussions for Cidofovir with buyers in Australia, New Zealand, Canada and South Korea.
- Evaluation and commercial quantities: 50 g samples for analytical qualification; 500 g and 1 kg for production. Pharmaceutical-grade crystalline powder. DMF reference letters available.
- Pallet quantities and production campaigns: repeat supply is coordinated against packaging, lead time, annual demand and destination-market import requirements.
> Quality & Documentation
Key specification parameters include assay (≥98.0%), related substances (individual ≤0.5%, total ≤1.5%), water content, residual solvents, heavy metals, optical rotation, and microbial limits. White to off-white crystalline powder. Soluble in water. Identity by HPLC and IR. Meets in-house pharmaceutical specifications aligned with ICH guidelines. COA, MSDS, and DMF documentation are standard.
> Packaging
Cidofovir is a white to off-white crystalline powder, soluble in water. Standard packaging includes double PE-lined foil bags in fibre drums (100 g, 500 g, or 1 kg). Store at controlled room temperature (15–25 °C). Protect from light. Shelf life is typically 36 months. Labels and documents are checked before dispatch.
> Pricing & MOQ
Pricing is quoted by specification, packaging and destination. Common commercial discussions use 25 kg bag/drum formats, pallet quantities and production-campaign planning; smaller samples may be reviewed for qualified formulation teams.
> Regulatory & Compounding Context
Cidofovir was FDA-approved in 1996 (Vistide) for CMV retinitis. EMA-authorized. On the WHO Model List of Essential Medicines. The original Vistide product has been discontinued in some markets. Generic cidofovir injection is available. Manufacturing requires antiviral API facilities. DMF support available.
> Alias Index
- INN: Cidofovir
- CAS Number: 113852-37-2
- Formula: C₈H₁₄N₃O₆P (MW 279.19)
- Brand name: Vistide (Gilead, discontinued in some markets)
- ATC code: J05AB12
- Chemical class: Acyclic nucleotide phosphonate
- Commercial request terms: cidofovir API, Vistide generic, CMV antiviral API, acyclic nucleotide, TCS Industries Limited
> FAQ
Why is Cidofovir active against resistant viruses?
Cidofovir is phosphorylated by cellular kinases, not viral thymidine kinase (TK). Therefore, TK-deficient acyclovir-resistant HSV and ganciclovir-resistant CMV strains remain susceptible. The cellular activation pathway also enables activity against viruses lacking their own kinases (adenovirus, polyomavirus, poxvirus).
What documents are available for Cidofovir orders?
COA and MSDS are standard for commercial discussions. COO, packing list, invoice and other import-support documents can be arranged according to order scope.
Do you supply Cidofovir to Australia and Canada?
Yes. We support B2B buyers in Australia, New Zealand, Canada and South Korea, subject to route and document review.
Do you supply New Zealand and South Korea?
Yes. We review Australia, New Zealand, Canada and South Korea for project supply, import documents, packaging and logistics planning before quotation.
What is the nephrotoxicity concern?
Cidofovir is nephrotoxic due to active uptake by proximal renal tubule cells via organic anion transporters. Probenecid (2 g pre-dose + 1 g at 2h and 8h) and aggressive IV hydration are co-administered to reduce renal accumulation. Serum creatinine and proteinuria must be monitored before each dose. Dose reduction or discontinuation is required for rising creatinine.
Is a DMF available?
Yes. TCS sources cidofovir from manufacturers who maintain active Drug Master Files. COA, stability data, and DMF reference letters are provided for generic dossier support. The API is manufactured under current regulatory compliance for antiviral API production.
Can you arrange samples before commercial purchasing?
Samples or evaluation quantities may be reviewed for qualified buyers after target specification, application and destination-market requirements are clarified.
How is Cidofovir packaged for export?
Packaging is confirmed by quantity and material properties. Typical options include foil bags, HDPE containers, fibre drums, 25 kg bags or palletized export packaging.
Can buyer-defined specifications be reviewed?
Yes. Send the specification, methods, impurity limits and required documents. TCS can review feasibility before confirming quotation and lead time.
What payment terms are normally used?
Standard payment is 100% T/T before dispatch unless a different arrangement has been approved for an established commercial account.
What lead time should buyers expect?
Lead time depends on stock, batch size, document scope and destination. Available stock can move faster; made-to-order or pallet programs require longer planning.
What off-label uses are documented?
IV cidofovir is used off-label for adenovirus infections in stem cell transplant recipients, BK virus nephropathy in kidney transplant recipients, and progressive multifocal leukoencephalopathy (JC virus). Intralesional cidofovir (2.5 mg/mL) is used for recurrent respiratory papillomatosis and cutaneous warts.
Last reviewed: June 2026
Evaluation and research orders (≤10 kg) are shipped with COA, MSDS, and certificate of origin. Bulk commercial orders (>10 kg) qualify for volume pricing with a full technical documentation package available on request.
> Request a Quote
If your team already has a target application, estimated quantity, destination market, or documentation requirements, send those details so the commercial response can be prepared more efficiently.